HSIC vs SNY
Henry Schein vs Sanofi — AI-powered side-by-side comparison
VS
SNY
Sanofi
62
Insufficient Data
| Metric | HSIC | SNY |
|---|
| AI Score |
67
|
62
|
| Price |
$89.16
|
$43.56
|
| P/E Ratio |
25.77×
|
23.06×
|
| ROE |
12.3%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
30.3%
|
72.8%
|
| Debt / Equity |
1.21×
|
0.34×
|
| Dividend Yield |
0.0%
|
5.5%
|
| RSI (14) |
59.4
|
53.1
|
| Beta |
0.808
|
0.278
|
| Expected Upside |
+0.8%
|
—
|
AI Committee View
Current Innellis committee reasoning for HSIC versus SNY.
HSIC leads by 5 points.
HSIC scores 67/100 (Buy) versus SNY at 62/100 (Insufficient Data).
HSIC Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
SNY Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Trend and market structure agree -- coherent bearish picture — Technical